Topics:

Cisplatin/Gemcitabine/Paclitaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer: A Southern Italy Cooperative Oncology Group (SICOG) Phase II Study

Cisplatin/Gemcitabine/Paclitaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer: A Southern Italy Cooperative Oncology Group (SICOG) Phase II Study

The purpose of this study was to define the antitumor activity of the PGT (cisplatin [Platinol]/gemcitabine [Gemzar]/paclitaxel [Taxol]) combination in chemonaive non–small-cell lung cancer patients.

Patients with locally advanced or metastatic NSCLC were considered eligible if they were £ 70 years old and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. They received cisplatin 50 mg/m², paclitaxel 125 mg/m², and gemcitabine 1,000 mg/m² days 1 and 8, every 3 week.

Beginning in April 1997, 39 patients with stage IIIB (13 patients) or IV (26) disease were enrolled for a total of 158 cycles delivered. The ECOG performance status was 0–1 in 31 patients and 2 in 8 patients. Of the 39 patients, 38 were evaluable for response on an intent-to-treat basis. Two complete responses and 24 partial responses have been recorded for a 68% (95% CI: 51%–82%) overall response rate. Major responses were 10/13 (77%) in stage IIIB patients and 16/25 (64%) in stage IV patients.

Patients’ quality-of-life (QoL) score improved in 27/38 (71%) patients. At a 13-month (range: 1–23 months) median follow-up the median survival time was 13.5 months, with a 1-year projected survival of 70%.

Toxicity was generally manageable. Grade 4 neutropenia and thrombocytopenia were observed in 9 (23%) and 3 (8%) patients, respectively, and in 6 cases a packed red blood cell transfusion was required. Severe nonhematologic toxicity occurred in 8 patients.

CONCLUSION: The PGT combination yields very high clinical response and QoL improvement in chemonaive advanced NSCLC patients, at a price of manageable toxicity. A large phase III trial comparing this new regimen to standard combinations is underway.

Click here for Dr. Vincent A. Miller’s commentary on this abstract.

 
Loading comments...
Please Wait 20 seconds or click here to close